SE500453C2 - Ett in vitro förfarande för utvärdering av en substans effekter - Google Patents

Ett in vitro förfarande för utvärdering av en substans effekter

Info

Publication number: SE500453C2
Authority: SE; Sweden
Prior art keywords: cells; solvent; hormone; receptors; containers
Prior art date: 1991-10-07

Application number

SE9102901A

Other languages

English (en)

Swedish (sv)

Other versions

SE9102901L (sv

SE9102901D0 (sv

Inventor

Stefan Nilsson

Maarten Oesterlund

Karin Heeroma

Original Assignee

Karobio Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-10-07

Filing date

1991-10-07

Publication date

1994-06-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20383927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE500453(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-10-07 Application filed by Karobio Ab filed Critical Karobio Ab

1991-10-07 Priority to SE9102901A priority Critical patent/SE500453C2/sv

1991-10-07 Publication of SE9102901D0 publication Critical patent/SE9102901D0/xx

1992-10-06 Priority to AU27735/92A priority patent/AU657171B2/en

1992-10-06 Priority to US08/211,487 priority patent/US5578445A/en

1992-10-06 Priority to EP92921468A priority patent/EP0607268B1/de

1992-10-06 Priority to AT92921468T priority patent/ATE156862T1/de

1992-10-06 Priority to CA002120604A priority patent/CA2120604C/en

1992-10-06 Priority to JP5506843A priority patent/JP2698476B2/ja

1992-10-06 Priority to DK92921468.2T priority patent/DK0607268T3/da

1992-10-06 Priority to ES92921468T priority patent/ES2104945T3/es

1992-10-06 Priority to DE69221629T priority patent/DE69221629T2/de

1992-10-06 Priority to PCT/SE1992/000698 priority patent/WO1993007290A1/en

1993-04-08 Publication of SE9102901L publication Critical patent/SE9102901L/

1994-04-06 Priority to NO19941246A priority patent/NO310439B1/no

1994-04-07 Priority to FI941611A priority patent/FI103672B/fi

1994-06-27 Publication of SE500453C2 publication Critical patent/SE500453C2/sv

1997-11-12 Priority to GR970402995T priority patent/GR3025354T3/el

Links

238000000034 method Methods 0.000 title claims abstract description 27
239000000126 substance Substances 0.000 title claims abstract description 21
238000000338 in vitro Methods 0.000 title claims abstract description 4
230000000694 effects Effects 0.000 title description 14
238000011156 evaluation Methods 0.000 title description 3
229940088597 hormone Drugs 0.000 claims abstract description 36
239000005556 hormone Substances 0.000 claims abstract description 36
238000012360 testing method Methods 0.000 claims abstract description 22
239000000556 agonist Substances 0.000 claims abstract description 16
239000005557 antagonist Substances 0.000 claims abstract description 16
230000036755 cellular response Effects 0.000 claims abstract description 15
102000005962 receptors Human genes 0.000 claims abstract description 15
108020003175 receptors Proteins 0.000 claims abstract description 15
108091008039 hormone receptors Proteins 0.000 claims abstract description 11
239000013558 reference substance Substances 0.000 claims abstract description 11
230000001270 agonistic effect Effects 0.000 claims abstract description 10
230000003042 antagnostic effect Effects 0.000 claims abstract description 10
230000003834 intracellular effect Effects 0.000 claims abstract description 9
230000010799 Receptor Interactions Effects 0.000 claims abstract description 6
108090000623 proteins and genes Proteins 0.000 claims description 27
239000002904 solvent Substances 0.000 claims description 27
102000004169 proteins and genes Human genes 0.000 claims description 13
230000001105 regulatory effect Effects 0.000 claims description 13
230000014509 gene expression Effects 0.000 claims description 11
238000004458 analytical method Methods 0.000 claims description 8
210000001519 tissue Anatomy 0.000 claims description 8
210000000481 breast Anatomy 0.000 claims description 7
210000004185 liver Anatomy 0.000 claims description 7
210000000988 bone and bone Anatomy 0.000 claims description 6
102000015694 estrogen receptors Human genes 0.000 claims description 6
108010038795 estrogen receptors Proteins 0.000 claims description 6
210000004696 endometrium Anatomy 0.000 claims description 5
210000002216 heart Anatomy 0.000 claims description 5
102000005969 steroid hormone receptors Human genes 0.000 claims description 5
108020003113 steroid hormone receptors Proteins 0.000 claims description 5
102000004217 thyroid hormone receptors Human genes 0.000 claims description 4
108090000721 thyroid hormone receptors Proteins 0.000 claims description 4
230000001419 dependent effect Effects 0.000 claims description 3
239000003862 glucocorticoid Substances 0.000 claims description 3
108050001049 Extracellular proteins Proteins 0.000 claims description 2
230000010261 cell growth Effects 0.000 claims description 2
108050000156 vitamin D receptors Proteins 0.000 claims description 2
102000009310 vitamin D receptors Human genes 0.000 claims description 2
210000004027 cell Anatomy 0.000 description 63
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 58
229960001603 tamoxifen Drugs 0.000 description 29
239000002609 medium Substances 0.000 description 27
238000007792 addition Methods 0.000 description 14
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 13
102100039175 Trefoil factor 1 Human genes 0.000 description 12
229930182833 estradiol Natural products 0.000 description 12
229960005309 estradiol Drugs 0.000 description 11
238000002474 experimental method Methods 0.000 description 10
206010006187 Breast cancer Diseases 0.000 description 9
208000026310 Breast neoplasm Diseases 0.000 description 9
102000040945 Transcription factor Human genes 0.000 description 7
108091023040 Transcription factor Proteins 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 6
229960003531 phenolsulfonphthalein Drugs 0.000 description 6
229940011871 estrogen Drugs 0.000 description 5
239000000262 estrogen Substances 0.000 description 5
102000002260 Alkaline Phosphatase Human genes 0.000 description 4
108020004774 Alkaline Phosphatase Proteins 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
230000006698 induction Effects 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
239000005495 thyroid hormone Substances 0.000 description 3
229940036555 thyroid hormone Drugs 0.000 description 3
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
102000003908 Cathepsin D Human genes 0.000 description 2
108090000258 Cathepsin D Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
108010088412 Trefoil Factor-1 Proteins 0.000 description 2
102000008817 Trefoil Factor-1 Human genes 0.000 description 2
229940046836 anti-estrogen Drugs 0.000 description 2
230000001833 anti-estrogenic effect Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000012258 culturing Methods 0.000 description 2
DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000328 estrogen antagonist Substances 0.000 description 2
230000001076 estrogenic effect Effects 0.000 description 2
238000010324 immunological assay Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000003270 steroid hormone Substances 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
102100033417 Glucocorticoid receptor Human genes 0.000 description 1
102100020948 Growth hormone receptor Human genes 0.000 description 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001036794 Microsorum maximum Species 0.000 description 1
102000005604 Myosin Heavy Chains Human genes 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
101710104378 Putative malate oxidoreductase [NAD] Proteins 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
108010068542 Somatotropin Receptors Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
108010051583 Ventricular Myosins Proteins 0.000 description 1
XYIPYISRNJUPBA-UHFFFAOYSA-N [3-(3'-methoxyspiro[adamantane-2,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC(C3)CC2C4)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 XYIPYISRNJUPBA-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000008484 agonism Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
235000005487 catechin Nutrition 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
229950001002 cianidanol Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
230000012010 growth Effects 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
102000027411 intracellular receptors Human genes 0.000 description 1
108091008582 intracellular receptors Proteins 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
230000009245 menopause Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
102000003998 progesterone receptors Human genes 0.000 description 1
108090000468 progesterone receptors Proteins 0.000 description 1
230000001373 regressive effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Pathology (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SE9102901A 1991-10-07 1991-10-07 Ett in vitro förfarande för utvärdering av en substans effekter SE500453C2 (sv)

Priority Applications (14)

Application Number	Priority Date	Filing Date	Title
SE9102901A SE500453C2 (sv)	1991-10-07	1991-10-07	Ett in vitro förfarande för utvärdering av en substans effekter
DE69221629T DE69221629T2 (de)	1991-10-07	1992-10-06	In vitro verfahren zur bewertung von effekten einer substanz
PCT/SE1992/000698 WO1993007290A1 (en)	1991-10-07	1992-10-06	An in vitro method of evaluating the effects of a substance
CA002120604A CA2120604C (en)	1991-10-07	1992-10-06	An in vitro method of evaluating the effects of a substance
ES92921468T ES2104945T3 (es)	1991-10-07	1992-10-06	Un metodo in vitro para evaluar los efectos de una sustancia.
EP92921468A EP0607268B1 (de)	1991-10-07	1992-10-06	In vitro verfahren zur bewertung von effekten einer substanz
AT92921468T ATE156862T1 (de)	1991-10-07	1992-10-06	In vitro verfahren zur bewertung von effekten einer substanz
AU27735/92A AU657171B2 (en)	1991-10-07	1992-10-06	An (in vitro) method of evaluating the effects of a substance
JP5506843A JP2698476B2 (ja)	1991-10-07	1992-10-06	物質の効果を評価するインビトロ法
DK92921468.2T DK0607268T3 (da)	1991-10-07	1992-10-06	In vitro fremgangsmåde til evaluering af virkningerne af et stof
US08/211,487 US5578445A (en)	1991-10-07	1992-10-06	In vitro method of evaluating the effects of a substance
NO19941246A NO310439B1 (no)	1991-10-07	1994-04-06	In vitro fremgangsmåte for evaluering av et stoffs virkninger
FI941611A FI103672B (fi)	1991-10-07	1994-04-07	Menetelmä aineen vaikutusten arvioimiseksi in vitro
GR970402995T GR3025354T3 (en)	1991-10-07	1997-11-12	AN -i(IN VITRO) METHOD OF EVALUATING THE EFFECTS OF A SUBSTANCE.

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9102901A SE500453C2 (sv)	1991-10-07	1991-10-07	Ett in vitro förfarande för utvärdering av en substans effekter

Publications (3)

Publication Number	Publication Date
SE9102901D0 SE9102901D0 (sv)	1991-10-07
SE9102901L SE9102901L (sv)	1993-04-08
SE500453C2 true SE500453C2 (sv)	1994-06-27

Family

ID=20383927

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9102901A SE500453C2 (sv)	1991-10-07	1991-10-07	Ett in vitro förfarande för utvärdering av en substans effekter

Country Status (14)

Country	Link
US (1)	US5578445A (de)
EP (1)	EP0607268B1 (de)
JP (1)	JP2698476B2 (de)
AT (1)	ATE156862T1 (de)
AU (1)	AU657171B2 (de)
CA (1)	CA2120604C (de)
DE (1)	DE69221629T2 (de)
DK (1)	DK0607268T3 (de)
ES (1)	ES2104945T3 (de)
FI (1)	FI103672B (de)
GR (1)	GR3025354T3 (de)
NO (1)	NO310439B1 (de)
SE (1)	SE500453C2 (de)
WO (1)	WO1993007290A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5461065A (en) *	1993-10-15	1995-10-24	Eli Lilly And Company	Methods for inhibiting endometriosis
US5461064A (en) *	1993-12-21	1995-10-24	Eli Lilly And Company	Methods of inhibiting atrophy of the skin and vagina
US6417198B1 (en) *	1993-12-21	2002-07-09	Eli Lilly And Company	Methods of inhibiting CNS problems in post-menopausal women
US6516294B1 (en)	1999-07-01	2003-02-04	The Regents Of The University Of California	Nuclear receptor for 1α,25-dihydroxyvitamin D3 useful for selection of vitamin D3 ligands and a method therefor
US20020001797A1 (en) *	2000-06-30	2002-01-03	Mitsuko Ishihara	Method for detecting endocrine disrupting action of a test substance
US20080085912A1 (en) *	2006-10-06	2008-04-10	Unitech Pharmaceuticals, Inc.	Isoxazole derivatives and methods of treating diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4859585A (en) *	1986-04-17	1989-08-22	Trustees Of Tufts College	In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US5071773A (en) *	1986-10-24	1991-12-10	The Salk Institute For Biological Studies	Hormone receptor-related bioassays
US5266464A (en) *	1988-02-10	1993-11-30	Ict Pharmaceuticals, Inc.	Method of screening for protein inhibitors and activators
US5091518A (en) *	1989-11-16	1992-02-25	The Salk Institute For Biological Studies	Beta retinoic acid response elements compositions and assays

1991
- 1991-10-07 SE SE9102901A patent/SE500453C2/sv not_active IP Right Cessation
1992
- 1992-10-06 EP EP92921468A patent/EP0607268B1/de not_active Revoked
- 1992-10-06 AT AT92921468T patent/ATE156862T1/de not_active IP Right Cessation
- 1992-10-06 DE DE69221629T patent/DE69221629T2/de not_active Revoked
- 1992-10-06 JP JP5506843A patent/JP2698476B2/ja not_active Expired - Fee Related
- 1992-10-06 ES ES92921468T patent/ES2104945T3/es not_active Expired - Lifetime
- 1992-10-06 DK DK92921468.2T patent/DK0607268T3/da active
- 1992-10-06 US US08/211,487 patent/US5578445A/en not_active Expired - Fee Related
- 1992-10-06 AU AU27735/92A patent/AU657171B2/en not_active Ceased
- 1992-10-06 WO PCT/SE1992/000698 patent/WO1993007290A1/en not_active Ceased
- 1992-10-06 CA CA002120604A patent/CA2120604C/en not_active Expired - Fee Related
1994
- 1994-04-06 NO NO19941246A patent/NO310439B1/no not_active IP Right Cessation
- 1994-04-07 FI FI941611A patent/FI103672B/fi active
1997
- 1997-11-12 GR GR970402995T patent/GR3025354T3/el unknown

Also Published As

Publication number	Publication date
AU657171B2 (en)	1995-03-02
CA2120604A1 (en)	1993-04-15
DK0607268T3 (da)	1997-09-08
EP0607268B1 (de)	1997-08-13
AU2773592A (en)	1993-05-03
ATE156862T1 (de)	1997-08-15
SE9102901L (sv)	1993-04-08
FI103672B1 (fi)	1999-08-13
FI941611L (fi)	1994-04-07
FI103672B (fi)	1999-08-13
EP0607268A1 (de)	1994-07-27
DE69221629D1 (de)	1997-09-18
NO941246D0 (no)	1994-04-06
ES2104945T3 (es)	1997-10-16
JP2698476B2 (ja)	1998-01-19
JPH07500184A (ja)	1995-01-05
DE69221629T2 (de)	1998-01-22
WO1993007290A1 (en)	1993-04-15
US5578445A (en)	1996-11-26
FI941611A0 (fi)	1994-04-07
NO310439B1 (no)	2001-07-02
GR3025354T3 (en)	1998-02-27
SE9102901D0 (sv)	1991-10-07
NO941246L (no)	1994-04-06
CA2120604C (en)	1999-08-17

Legal Events

Date	Code	Title	Description
2008-06-17	NUG	Patent has lapsed

Publication	Publication Date	Title
Zhu et al.	1996	Estrogen and thyroid hormone interaction on regulation of gene expression.
Kawai et al.	2007	Growth hormone stimulates adipogenesis of 3T3-L1 cells through activation of the Stat5A/5B-PPARγ pathway
Heikkilä et al.	2002	Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production
Soares et al.	2004	Evidence for the notch signaling pathway on the role of estrogen in angiogenesis
Christenson et al.	1996	Proliferation of microvascular endothelial cells in the primate corpus luteum during the menstrual cycle and simulated early pregnancy
Sun et al.	2016	FAK promotes osteoblast progenitor cell proliferation and differentiation by enhancing Wnt signaling
Neumann et al.	2002	Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro
Bergh et al.	2004	Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel
Wang et al.	1998	Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function
Miyoshi et al.	2006	Mutual regulation of follicle-stimulating hormone signaling and bone morphogenetic protein system in human granulosa cells
Dubois et al.	2015	Enobosarm (GTx-024) modulates adult skeletal muscle mass independently of the androgen receptor in the satellite cell lineage
Kim et al.	2015	Regulation of mesenchymal stromal cells through fine tuning of canonical Wnt signaling
Yang et al.	2005	Expression and activity of C/EBPβ and δ are upregulated by dexamethasone in skeletal muscle
Yu et al.	2015	Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation
Santen et al.	2003	Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
François et al.	2015	17β-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1
Pu et al.	2007	Androgen regulation of prostate morphoregulatory gene expression: Fgf 10-dependent and-independent pathways
Matemba et al.	2006	Regulation of osteoclastogenesis by gap junction communication
Haisenleder et al.	2003	Gonadotropin-releasing hormone stimulation of gonadotropin subunit transcription: evidence for the involvement of calcium/calmodulin-dependent kinase II (Ca/CAMK II) activation in rat pituitaries
Nguyen et al.	2004	Acute regulation of translation initiation by gonadotropin-releasing hormone in the gonadotrope cell line LβT2
Juliano et al.	1976	Estrogen receptors in the rat uterus. Retention of hormone-receptor complexes
KR20130137164A (ko)	2013-12-16	지방생성 및 근섬유모세포 분화 제어 작용제에 대한 세포 배양 스크리닝
SE500453C2 (sv)	1994-06-27	Ett in vitro förfarande för utvärdering av en substans effekter
Attardi et al.	1997	Glucocorticoid repression of gonadotropin-releasing hormone gene expression and secretion in morphologically distinct subpopulations of GT1-7 cells
Yan et al.	2001	Differential expression and regulation of the retinoblastoma family of proteins during testicular development and spermatogenesis: roles in the control of germ cell proliferation, differentiation and apoptosis